Altris AI launches advanced glaucoma Optic Disc Analysis module

News
Article

Key parameters captured by the module include disc area, cup area, cup volume, minimal cup depth, maximum cup depth, cup/disc area ratio, rim absence angle, and disc-damage likelihood scale.

AI graphic of motherboard Image credit: AdobeStock/Kaikoro

Image credit: AdobeStock/Kaikoro

Altris AI has announced the launch of an advanced glaucoma Optic Disc Analysis module intended to aid in the early detection of the disease. The new artificial intelligence (AI) module builds upon an earlier innovation that utilizes Ganglion Cell Complex (GCC) Asymmetry Analysis that will enhance improvements from the Altris AI macula module, according to a news release.

“The launch of our Advanced Optic Disc Analysis module marks a pivotal step forward in glaucoma care,” said Maria Znamenska, MD, PhD, chief medical officer at Altris AI, in the release. “By combining the gold standard of optic disc evaluation with AI-powered precision, we’re equipping eye care professionals with the tools to make more accurate and timely diagnosis of this vision-threatening disorder. This innovation not only reduces false positive referrals but also enhances early detection and treatment planning—ensuring better outcomes for patients and optimizing healthcare resources. Together with GCC asymmetry analysis, our platform empowers clinicians to elevate the standard of glaucoma care, offering hope to millions at risk of vision loss.”

Key parameters captured by the module include disc area, cup area, cup volume, minimal cup depth, maximum cup depth, cup/disc area ratio, rim absence angle, and disc-damage likelihood scale. Optic disc parameters are evaluated by the module using optical coherence tomography (OCT), which allows for personalized assessments by accounting for individual disc sizes and angle of rim absence. Additionally, the platform assigns a severity score for optic disc damage on a scale of 1 to 10.

The Altris Glaucoma Module is compatible with 3D OCT optic disc, horizontal wide, and vertical-wide scans, as well as OCT optic disc raster scans. Cross-evaluation is available across these OCT systems, which allows eye care providers to analyze both macula and optic disc pathology, even if data originates from multiple OCT devices.

Altris launched its AI-powered Advanced Optic Disc Analysis module in February 2025.

Reference
  1. Altris AI launches advanced Optic Disc Analysis for glaucoma. News release. Altris AI. Accessed March 3, 2025. https://www.altris.ai/article/altris-ai-launches-advanced-optic-disc-analysis-for-glaucoma-complementing-gcc-asymmetry-analysis/
Recent Videos
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Dr. Julie Rodman previews her SECO presentations
Three EnVision Summit faculty members weigh in on the importance of comanagement in glaucoma management, where artificial intelligence will lead eye care, and what hopes are on the horizon for corneal ectasia treatments.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
© 2025 MJH Life Sciences

All rights reserved.